Quantbot Technologies LP Invests $5.44 Million in Cardinal Health, Inc. $CAH

Key Points

• Quantbot Technologies acquired 22,912 Cardinal Health shares during the second quarter, valued at approximately $5.44 million. Institutional investors collectively own 87.17% of the company.
• Analysts remain broadly positive, with 16 Buy ratings and three Holds; Cardinal Health has a “Moderate Buy” consensus rating and an average price target of $266.56.
• Cardinal Health reported quarterly EPS of $2.91, beating estimates of $2.42, while revenue rose 5.8% year over year. However, executives—including the CEO—sold substantial amounts of stock, and investors may question the sustainability of earnings growth partly linked to a one-time tariff refund.

Quantbot Technologies LP acquired a new position in Cardinal Health, Inc. (NYSE:CAH - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,912 shares of the company's stock, valued at approximately $5,443,000.

A number of other hedge funds have also added to or reduced their stakes in CAH. University of Texas Texas AM Investment Management Co. bought a new stake in Cardinal Health during the 4th quarter worth about $26,000. Bank of Jackson Hole Trust acquired a new position in shares of Cardinal Health during the 4th quarter worth about $27,000. Jones Financial Companies Lllp grew its holdings in shares of Cardinal Health by 198.3% in the 1st quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company's stock valued at $27,000 after acquiring an additional 14,034 shares in the last quarter. Palladiem LLC acquired a new stake in shares of Cardinal Health in the fourth quarter valued at about $28,000. Finally, Indiana Trust & Investment Management Co acquired a new stake in shares of Cardinal Health in the first quarter valued at about $29,000. Institutional investors own 87.17% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Royal Bank Of Canada initiated coverage on Cardinal Health in a research report on Wednesday. They set an "outperform" rating and a $276.00 price target for the company. William Blair initiated coverage on Cardinal Health in a report on Tuesday, April 28th. They issued an "outperform" rating for the company. Zacks Research downgraded shares of Cardinal Health from a "strong-buy" rating to a "hold" rating in a report on Friday, June 12th. Leerink Partners set a $292.00 price target on shares of Cardinal Health in a research note on Tuesday, August 11th. Finally, Citigroup boosted their price objective on shares of Cardinal Health from $265.00 to $280.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $266.56.

Insider Activity

In other news, CEO Jason M. Hollar sold 44,529 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the sale, the chief executive officer directly owned 190,603 shares in the company, valued at approximately $45,016,616.54. This trade represents a 18.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michelle D. Greene sold 11,650 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the completion of the sale, the insider owned 10,330 shares in the company, valued at $2,434,987.60. This represents a 53.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 210,271 shares of company stock valued at $49,626,657. Corporate insiders own 0.12% of the company's stock.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Cardinal Health Trading Up 0.4%

NYSE:CAH opened at $229.48 on Friday. The stock has a market cap of $53.37 billion, a P/E ratio of 31.74, a PEG ratio of 1.23 and a beta of 0.49. The stock has a 50 day simple moving average of $232.02 and a 200 day simple moving average of $217.86. Cardinal Health, Inc. has a 1-year low of $145.87 and a 1-year high of $258.30.

Cardinal Health (NYSE:CAH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.42 by $0.49. The firm had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, sell-side analysts forecast that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a dividend of $0.5158 per share. This represents a $2.06 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, October 1st. Cardinal Health's payout ratio is currently 28.49%.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source